Physician profile
Shannon Howe
NPI 1316986094
$3,635.66
in general payments reported to CMS, 2019-2025
20 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.97 · 2020: $50.67 · 2021: $202 · 2022: $177 · 2023: $302 · 2024: $1,578 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,163 · Education: $31.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,162.77 |
| Education | $31.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $749.82 | 2021-2025 | |
| Ucb, INC. | $565.76 | 2023-2025 | Cimzia, Bimzelx |
| Amgen INC. | $446.29 | 2020-2025 | Tavneos, Krystexxa, Enbrel |
| Pfizer INC. | $373.13 | 2019-2025 | |
| Janssen Biotech, INC. | $360.74 | 2022-2025 | Tremfya, Stelara, Simponi |
| Mallinckrodt Hospital Products INC. | $224.05 | 2024-2025 | Acthar |
| Radius Health, INC. | $170.47 | 2024-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $166.67 | 2021-2024 | Saphnelo |
| Janssen Scientific Affairs, LLC | $124.98 | 2022 | |
| Glaxosmithkline, LLC. | $93.43 | 2022-2025 | Benlysta |
| Regeneron Healthcare Solutions, INC. | $87.25 | 2024-2025 | Dupixent |
| Biocon Biologics INC | $66.46 | 2024 | Hulio |
| Takeda Pharmaceuticals U.S.A., INC. | $46.56 | 2025 | Entyvio |
| Almatica Pharma LLC | $34.92 | 2024 | Teriparatide |
| Genzyme Corporation | $27.28 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $23.40 | 2024 | Resmetirom |
| Lilly USA, LLC | $23.04 | 2024 | Taltz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.61 | 2025 | Xifaxan |
| Actelion Pharmaceuticals US, INC. | $17.30 | 2024 | Uptravi, Opsumit |
| Aimmune Therapeutics, INC. | $16.50 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Howe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.